ROP-TB diagnostic assay achieves 94.49% overall agreement with T-SPOT.TB for tuberculosis detection
Background
Accurate and scalable diagnostics for Tuberculosis (TB) remain a critical global health challenge, as it continues to be a leading cause of death from infectious disease. Current interferon-gamma release assays (IGRAs), such as ELISPOT-based T-SPOT.TB, rely on pooled synthetic peptides. This approach presents significant hurdles for large-scale Good Manufacturing Practice (GMP) production and consistent quality control, limiting their widespread accessibility and cost-effectiveness. The need for a more robust and easily manufacturable diagnostic platform that maintains high accuracy, especially for latent and drug-resistant strains, is paramount.
Study Design
Researchers developed a novel recombinant overlapping peptide (ROP) technology to address the manufacturing and quality control limitations of existing IGRAs. They conducted a multi-center clinical trial in China from September 2021 to August 2022 to evaluate the diagnostic performance of ROP-TB. The study compared ROP-TB against the established T-SPOT.TB assay, which served as the comparator. The primary endpoint was the agreement rate between the two diagnostic methods, assessing positive, negative, and overall concordance, alongside sensitivity and specificity. The trial utilized two distinct reagents within the ROP-TB platform, designed to represent different antigen presentation pathways.
Results
The ROP-TB assay demonstrated excellent agreement with the T-SPOT.TB diagnostic, indicating its strong potential as a comparable diagnostic tool. Specifically, the positive agreement rate between ROP-TB and T-SPOT.TB was 95.29%, while the negative agreement rate reached 93.51%. The overall agreement rate between the two assays was remarkably high at 94.49%, with a strong Kappa statistic of κ = 0.889, confirming significant concordance (p < 0.001). > ROP-TB achieved a sensitivity of 88.03% and a specificity of 76.79% for tuberculosis detection. Furthermore, the study observed that ROP-TB elicited a significantly stronger immune response amplitude in individuals diagnosed with presumed latent tuberculosis and those with drug-resistant tuberculosis strains, suggesting enhanced detection capabilities for these challenging patient populations.
Key Findings
- ROP-TB showed 94.49% overall agreement with T-SPOT.TB (κ = 0.889, p < 0.001).
- Positive agreement rate was 95.29% and negative agreement rate was 93.51%.
- ROP-TB achieved 88.03% sensitivity and 76.79% specificity.
- ROP-TB elicited a significantly stronger immune response in latent and drug-resistant TB.
- The technology addresses
GMPproduction and quality control challenges of currentIGRAs.
Why It Matters
This study introduces a more scalable and quality-controlled diagnostic option for TB, potentially overcoming the manufacturing limitations of current IGRAs. For clinicians and public health initiatives, ROP-TB offers a viable auxiliary diagnostic and screening tool that performs comparably to the established T-SPOT.TB. The enhanced detection of latent and drug-resistant TB strains is particularly significant, as these forms are often harder to diagnose and manage, impacting treatment outcomes and disease transmission. This advancement could lead to earlier intervention and more effective control strategies, especially in high-burden regions. While a usable protocol is still in the clinical evaluation phase, the foundational technology is promising for future widespread adoption.
tuberculosis
diagnosis
igra
rop-tb
clinical-trial
infectious-disease